Sarcoma, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
Conditions
Brief summary
This is a study evaluating the safety and efficacy of Lattice SBRT for patients with large tumors (≥ 4.5 cm) planning to undergo palliative radiotherapy.
Interventions
RADIATIONStereotactic body radiotherapy
Treatment will take approximately 2 weeks.
PROCEDUREResearch blood draw
-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
Sponsors
Goldman Sachs Foundation (Emerson Collective)
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
At least 10 participants will be enrolled in each cohort (soft tissue sarcomas, thoracic cancers, abdominal, and pelvic cancers).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed sarcoma (including extremity), thoracic cancer (including esophageal), abdominal cancer (including retroperitoneal sarcoma), or pelvic cancer. * Planning to undergo palliative radiotherapy to a lesion ≥ 4.5 cm as measured with radiographic imaging or with calipers by clinical exam. * ECOG performance status ≤ 2 * At least 18 years of age. * Radiotherapy is known to be teratogenic. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 6 months after completion of the study * Ability to understand and willingness to sign an IRB approved written informed consent document
Exclusion criteria
* Prior high-dose radiotherapy that overlaps with any planned site of protocol radiotherapy. Patients where the Lattice SBRT fields may overlap with the low dose (\<10 Gy) region of prior radiotherapy treatments are eligible and may be treated if this is determined to be safe by the treating physician. * Patients with tumors in need of urgent surgical intervention, such as life-threatening bleeding or those at high risk for pathologic fracture. * Currently receiving any cytotoxic cancer therapy regimens or VEGF inhibitors that will overlap with the Lattice SBRT administration. \*Cytotoxic chemotherapy and VEGF inhibitors prior to radiotherapy or planned after radiotherapy delivery are allowed at the discretion of the treating radiation oncologist. This includes continuing a treatment plan which was initiated prior to the start of radiotherapy. A 2-week washout is recommended, but not required. * Pregnant. Women of childbearing potential must have a negative pregnancy test within 20 days of study entry. * Patients with HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e. for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Local Control | At 6 months | — |
| Number of Participants With Treatment-related, Non-hematologic Grade ≥ 3 Toxicity | Through 6 months | -Graded using CTCAE v5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline-PROMIS Depression Assessment | 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Depression is a 4-item questionnaire assessing current self-reported depression with answers ranging from 1=never to 5=always * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Depression Assessment correlates to more depression, or negative outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or worse depression, than the reference population mean |
| Mean Change From Baseline-PROMIS Anxiety Assessment | 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Anxiety is a 29-item questionnaire assessing current self-reported anxiety with answers ranging from 1=never to 5=always * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Anxiety Assessment correlates to more anxiety, or negative outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or worse anxiety, than the reference population mean. |
| Mean Change From Baseline-Numeric Pain Scale | 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * Each value is the mean of the changes from baseline Numeric Pain Scale score to timepoint Numeric Pain Scale score. * The Numeric Pain Scale is an 11-point scale for patient self-reporting of pain * The Numeric Pain Rating Scale (NPRS) measures pain intensity in adults using a scale from 0 or no pain to 10 or worst possible pain. This measure is unidimensional and evaluated on the 0-10 scale. A higher value on the scale correlates with a worse pain and a worse outcome. |
| Mean Change From Baseline - PROMIS Physical Function Assessment | 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Physical Function is a 10-item questionnaire assessing current self-reported physical function with answers ranging from 1 = cannot do to 5 = not at all/without any difficulty. * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Physical Function Assessment correlates to a higher physical function, or positive outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or better functioning, than the reference population mean. |
| Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * How often options include 1=never, 2=rarely, 3=occasionally, 4=frequently, 5=almost constantly * Severity of difficulty getting/keeping erection, ejaculation problems, decreased sexual interest, vaginal pain 1=none, 2=mild, 3=moderate, 4=severe, 5=very severe * Experienced unusual vaginal discharge options include 1=not at all, 2=a little bit, 3 = somewhat, 4=quite a bit, 5=very much |
| Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * Frequency options include never=1, rarely=2, occasionally=3, frequently=4, almost constantly=5 |
| Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * Frequency options include never=1, rarely=2, occasionally=3, frequently=4, almost constantly=5 |
| Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * Frequency options include never=1, rarely=2, occasionally=3, frequently=4, almost constantly=5 |
| Mean Change From Baseline-PROMIS Global Health Physical Assessment | 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months | * Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Global Health is a 2-item questionnaire assessing current self-reported physical function with answers ranging from 1=poor/not all all to 5=excellent/completely * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Global Health Physical Assessment correlates to a higher global health physical assessment, or positive outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or better physical assessment, than the reference population mean |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SBRT 5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy. | 70 |
| Total | 70 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 1 |
| Overall Study | Did not start treatment on protocol | 3 |
Baseline characteristics
| Characteristic | SBRT |
|---|---|
| Age, Continuous | 65.5 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 69 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 11 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 57 Participants |
| Region of Enrollment United States | 70 participants |
| Sex: Female, Male Female | 27 Participants |
| Sex: Female, Male Male | 43 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 33 / 66 |
| other Total, other adverse events | 31 / 66 |
| serious Total, serious adverse events | 42 / 66 |
Outcome results
Primary
Number of Participants With Treatment-related, Non-hematologic Grade ≥ 3 Toxicity
-Graded using CTCAE v5.0
Time frame: Through 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SBRT | Number of Participants With Treatment-related, Non-hematologic Grade ≥ 3 Toxicity | 2 Participants |
Primary
Rate of Local Control
Time frame: At 6 months
Population: Participants must have received treatment and had a 6 month disease assessment to be evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| SBRT | Rate of Local Control | 29 Participants |
Secondary
Mean Change From Baseline-Numeric Pain Scale
* Each value is the mean of the changes from baseline Numeric Pain Scale score to timepoint Numeric Pain Scale score. * The Numeric Pain Scale is an 11-point scale for patient self-reporting of pain * The Numeric Pain Rating Scale (NPRS) measures pain intensity in adults using a scale from 0 or no pain to 10 or worst possible pain. This measure is unidimensional and evaluated on the 0-10 scale. A higher value on the scale correlates with a worse pain and a worse outcome.
Time frame: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SBRT | Mean Change From Baseline-Numeric Pain Scale | 0.87 score on a scale | Standard Deviation 3.911571967 |
| SBRT-30 Days | Mean Change From Baseline-Numeric Pain Scale | -0.38 score on a scale | Standard Deviation 4.209848701 |
| SBRT-3 Months | Mean Change From Baseline-Numeric Pain Scale | -0.83 score on a scale | Standard Deviation 2.357715744 |
| SBRT-6 Months | Mean Change From Baseline-Numeric Pain Scale | -0.29 score on a scale | Standard Deviation 3.709210396 |
| SBRT-12 Months | Mean Change From Baseline-Numeric Pain Scale | -0.77 score on a scale | Standard Deviation 2.832956234 |
Secondary
Mean Change From Baseline-PROMIS Anxiety Assessment
* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Anxiety is a 29-item questionnaire assessing current self-reported anxiety with answers ranging from 1=never to 5=always * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Anxiety Assessment correlates to more anxiety, or negative outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or worse anxiety, than the reference population mean.
Time frame: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SBRT | Mean Change From Baseline-PROMIS Anxiety Assessment | 1.16 T-Score | Standard Deviation 7.520188855 |
| SBRT-30 Days | Mean Change From Baseline-PROMIS Anxiety Assessment | 0.12 T-Score | Standard Deviation 6.799064792 |
| SBRT-3 Months | Mean Change From Baseline-PROMIS Anxiety Assessment | -1.66 T-Score | Standard Deviation 8.797717813 |
| SBRT-6 Months | Mean Change From Baseline-PROMIS Anxiety Assessment | -0.15 T-Score | Standard Deviation 8.436791296 |
| SBRT-12 Months | Mean Change From Baseline-PROMIS Anxiety Assessment | -4.34 T-Score | Standard Deviation 9.955565864 |
Secondary
Mean Change From Baseline-PROMIS Depression Assessment
* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Depression is a 4-item questionnaire assessing current self-reported depression with answers ranging from 1=never to 5=always * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Depression Assessment correlates to more depression, or negative outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or worse depression, than the reference population mean
Time frame: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SBRT | Mean Change From Baseline-PROMIS Depression Assessment | 1.01 T-Score | Standard Deviation 6.575515969 |
| SBRT-30 Days | Mean Change From Baseline-PROMIS Depression Assessment | 0.72 T-Score | Standard Deviation 7.013388007 |
| SBRT-3 Months | Mean Change From Baseline-PROMIS Depression Assessment | -0.15 T-Score | Standard Deviation 7.290691563 |
| SBRT-6 Months | Mean Change From Baseline-PROMIS Depression Assessment | 1.01 T-Score | Standard Deviation 9.929482946 |
| SBRT-12 Months | Mean Change From Baseline-PROMIS Depression Assessment | -2.43 T-Score | Standard Deviation 8.78069853 |
Secondary
Mean Change From Baseline-PROMIS Global Health Physical Assessment
* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Global Health is a 2-item questionnaire assessing current self-reported physical function with answers ranging from 1=poor/not all all to 5=excellent/completely * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Global Health Physical Assessment correlates to a higher global health physical assessment, or positive outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or better physical assessment, than the reference population mean
Time frame: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SBRT | Mean Change From Baseline-PROMIS Global Health Physical Assessment | 1.36 T-Score | Standard Deviation 4.885644726 |
| SBRT-30 Days | Mean Change From Baseline-PROMIS Global Health Physical Assessment | 0.40 T-Score | Standard Deviation 5.629643682 |
| SBRT-3 Months | Mean Change From Baseline-PROMIS Global Health Physical Assessment | 0.95 T-Score | Standard Deviation 6.704716684 |
| SBRT-6 Months | Mean Change From Baseline-PROMIS Global Health Physical Assessment | 2.63 T-Score | Standard Deviation 7.152040563 |
| SBRT-12 Months | Mean Change From Baseline-PROMIS Global Health Physical Assessment | 1.06 T-Score | Standard Deviation 5.996095952 |
Secondary
Mean Change From Baseline - PROMIS Physical Function Assessment
* Each value is the mean of the changes from baseline PROMIS T-Score to timepoint PROMIS T-score. * PROMIS Physical Function is a 10-item questionnaire assessing current self-reported physical function with answers ranging from 1 = cannot do to 5 = not at all/without any difficulty. * A PROMIS T-Score of 50 corresponds to the mean of the general population. A magnitude of 10 on the PROMIS scale corresponds to a standard deviation. * A high T-Score for PROMIS Physical Function Assessment correlates to a higher physical function, or positive outcome. Since the scale is standardized a score of 60 is one standard deviation higher, or better functioning, than the reference population mean.
Time frame: 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SBRT | Mean Change From Baseline - PROMIS Physical Function Assessment | 2.22 T-Score | Standard Deviation 5.976098077 |
| SBRT-30 Days | Mean Change From Baseline - PROMIS Physical Function Assessment | -0.27 T-Score | Standard Deviation 6.464353622 |
| SBRT-3 Months | Mean Change From Baseline - PROMIS Physical Function Assessment | 2.01 T-Score | Standard Deviation 8.493109161 |
| SBRT-6 Months | Mean Change From Baseline - PROMIS Physical Function Assessment | 2.76 T-Score | Standard Deviation 8.144051291 |
| SBRT-12 Months | Mean Change From Baseline - PROMIS Physical Function Assessment | -0.72 T-Score | Standard Deviation 6.097212478 |
Secondary
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites)
* The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * Frequency options include never=1, rarely=2, occasionally=3, frequently=4, almost constantly=5
Time frame: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included. If the participant did not answer a question on the questionnaire then they are not included for that question.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of abdominal pain | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of abdominal pain | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of decreased appetite | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of diarrhea | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of pain | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of constipation | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Bowel movement control loss interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bowel movement control loss | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Abdominal pain interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of concentration problems | 1.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of pain | 4 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of memory problems | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Decreased appetite interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of constipation | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of nausea | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of diarrhea | 1.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of abdominal pain | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of decreased appetite | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of abdominal pain | 2.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Abdominal pain interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bowel movement control loss | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Bowel movement control loss interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of nausea | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of abdominal pain | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of pain | 4 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of abdominal pain | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of nausea | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Abdominal pain interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bowel movement control loss | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of memory problems | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of constipation | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Bowel movement control loss interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of depression | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of decreased appetite | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of diarrhea | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of nausea | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of decreased appetite | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bloating | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of bloating | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of constipation | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of diarrhea | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of abdominal pain | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of abdominal pain | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Abdominal pain interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bowel movement control loss | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Bowel movement control loss interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of pain | 3 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of insomnia | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Fatigue interference | 2.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of anxiety | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of sadness or unhappiness | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of sadness or unhappiness | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Bowel movement control loss interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of abdominal pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of abdominal pain | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bowel movement control loss | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of nausea | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of decreased appetite | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of diarrhea | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of anxiety | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of nausea | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of constipation | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Abdominal pain interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of sadness or unhappiness | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Bowel movement control loss interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of nausea | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of insomnia | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bowel movement control loss | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Abdominal pain interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of abdominal pain | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of fatigue | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of abdominal pain | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of diarrhea | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of constipation | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of sadness or unhappiness | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of bloating | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of bloating | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of decreased appetite | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of nausea | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Gastrointestinal Cancer Sites) | Severity of dizziness | 1 score on a scale |
Secondary
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites)
* The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * How often options include 1=never, 2=rarely, 3=occasionally, 4=frequently, 5=almost constantly * Severity of difficulty getting/keeping erection, ejaculation problems, decreased sexual interest, vaginal pain 1=none, 2=mild, 3=moderate, 4=severe, 5=very severe * Experienced unusual vaginal discharge options include 1=not at all, 2=a little bit, 3 = somewhat, 4=quite a bit, 5=very much
Time frame: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included. If the participant did not answer a question on the questionnaire then they are not included for that question.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urge to urinate interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urine leakage | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of difficulty getting/keeping an erection | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of vaginal dryness | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain during vaginal sex | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urination frequency | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain/burning with urination | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of decreased sexual interest | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Experienced unusual vaginal discharge | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of pain | 4 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequent urination interfering | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urge to urinate | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Pain interference | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of ejaculation problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urine leakage frequency | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of memory problems | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain/burning with urination | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urine leakage | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urge to urinate interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Experienced unusual vaginal discharge | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of difficulty getting/keeping an erection | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urine leakage frequency | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of vaginal dryness | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Anxiety interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urge to urinate | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of ejaculation problems | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of pain | 3.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urination frequency | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequent urination interfering | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Pain interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of concentration problems | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of decreased sexual interest | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Experienced unusual vaginal discharge | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequent urination interfering | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of vaginal dryness | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of concentration problems | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain/burning with urination | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urge to urinate | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urge to urinate interference | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urination frequency | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of decreased sexual interest | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of pain | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of ejaculation problems | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain during vaginal sex | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of difficulty getting/keeping an erection | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of fatigue | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urine leakage frequency | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urine leakage | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urge to urinate | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of difficulty getting/keeping an erection | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of insomnia | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Pain interference | 3 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Experienced unusual vaginal discharge | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urine leakage | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of concentration problems | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequent urination interfering | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of pain | 3.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of ejaculation problems | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain/burning with urination | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of memory problems | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain during vaginal sex | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of vaginal dryness | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of decreased sexual interest | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urge to urinate interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urine leakage frequency | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urination frequency | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Fatigue interference | 3.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of fatigue | 3.5 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urge to urinate | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of numbness/tingling in hands or feet | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of dizziness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of pain | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Insomnia interference | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Experienced unusual vaginal discharge | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of vaginal dryness | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain/burning with urination | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urge to urinate interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urination frequency | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequent urination interfering | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urine leakage | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urine leakage frequency | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of difficulty getting/keeping an erection | 2.5 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of ejaculation problems | 2.5 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of decreased sexual interest | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain during vaginal sex | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain during vaginal sex | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequent urination interfering | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Depression interference | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of depression | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of decreased sexual interest | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urine leakage | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of depression | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Anxiety interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of anxiety | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of anxiety | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of dizziness | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urine leakage frequency | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Fatigue interference | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Insomnia interference | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of difficulty getting/keeping an erection | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Pain interference | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of pain | 4 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Memory problem interference | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of ejaculation problems | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of memory problems | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Concentration problems interference | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of concentration problems | 1.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Urge to urinate interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urge to urinate | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Dizziness interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Frequency of urination frequency | 2.5 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of pain/burning with urination | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Severity of vaginal dryness | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Experienced unusual vaginal discharge | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Pelvic Cancer Sites) | Sadness or happiness interference | 1.5 score on a scale |
Secondary
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites)
* The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * Frequency options include never=1, rarely=2, occasionally=3, frequently=4, almost constantly=5
Time frame: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included. If the participant did not answer a question on the questionnaire then they are not included for that question.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Pain interference | 2.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Depression interference | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of sadness or unhappiness | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Anxiety interference | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of numbness/tingling in hands or feet | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Mouth or throat sores interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Numbness or tingling in hands or feet interference | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of difficulty swallowing | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dry mouth | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dizziness | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of mouth or throat sores | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of depression | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of skin cracking at corners of mouth | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Fatigue interference | 3.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Dizziness interference | 2.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of pain | 2.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Sadness or happiness interference | 2.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of fatigue | 3.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of pain | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of sadness or unhappiness | 3.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of depression | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of hoarse voice | 1.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Pain interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of mouth or throat sores | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of pain | 4 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of pain | 4 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Depression interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Mouth or throat sores interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of depression | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dry mouth | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of skin cracking at corners of mouth | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of depression | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of hoarse voice | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Anxiety interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of anxiety | 2.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of anxiety | 2.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of difficulty swallowing | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Fatigue interference | 3.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of fatigue | 3.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Insomnia interference | 2.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of pain | 4.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dry mouth | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of difficulty swallowing | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of mouth or throat sores | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Mouth or throat sores interference | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of numbness/tingling in hands or feet | 2.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of skin cracking at corners of mouth | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Numbness or tingling in hands or feet interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dizziness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Dizziness interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of concentration problems | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Concentration problems interference | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of memory problems | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Memory problem interference | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of pain | 4.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Pain interference | 4 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Insomnia interference | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of fatigue | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of anxiety | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of anxiety | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of sadness or unhappiness | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Sadness or happiness interference | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Anxiety interference | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Fatigue interference | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of skin cracking at corners of mouth | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of sadness or unhappiness | 2.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of depression | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of sadness or unhappiness | 2.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Numbness or tingling in hands or feet interference | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Mouth or throat sores interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of difficulty swallowing | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of depression | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of fatigue | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dry mouth | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Depression interference | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of pain | 4.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Insomnia interference | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of numbness/tingling in hands or feet | 3.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of pain | 4 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of mouth or throat sores | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Pain interference | 3 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of insomnia | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of depression | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of insomnia | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Insomnia interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of fatigue | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Fatigue interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of anxiety | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of dry mouth | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of skin cracking at corners of mouth | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of difficulty swallowing | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Mouth or throat sores interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of mouth or throat sores | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Sarcoma Cancer Sites) | Concentration problems interference | 1 score on a scale |
Secondary
Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites)
* The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The higher the score the worst the symptoms. * Severity options include none=1, mild=2, moderate=3, severe = 4, very severe=5. * Interference options include not at all=1, a little bit=2, somewhat=3, quite a bit=4, very much=5 * Frequency options include never=1, rarely=2, occasionally=3, frequently=4, almost constantly=5
Time frame: Baseline, 2 weeks post-treatment (approximately week 4), 30 days, 3 months, 6 months, and 12 months
Population: If a participant did not complete the questionnaire at the timepoint then they are not included.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of decreased appetite | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of bloating | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of shortness of breath | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Shortness of breath interference | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of wheezing | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Fatigue interference | 2.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of depression | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of depression | 1.5 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Pain interference | 3.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of pain | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of pain | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Memory problem interference | 1.5 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Decreased appetite interference | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of decreased appetite | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of shortness of breath | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Shortness of breath interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of wheezing | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of anxiety | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-30 Days | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of shortness of breath | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of sadness or unhappiness | 1.5 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Shortness of breath interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of bloating | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of wheezing | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of bloating | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of decreased appetite | 2 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-3 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of depression | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of depression | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of shortness of breath | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Shortness of breath interference | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of wheezing | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of memory problems | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of pain | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Insomnia interference | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of fatigue | 2.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of anxiety | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hoarse voice | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of decreased appetite | 1.5 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT-6 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of bloating | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of insomnia | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Numbness or tingling in hands or feet interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of numbness/tingling in hands or feet | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Fatigue interference | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of wheezing | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of anxiety | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Shortness of breath interference | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of anxiety | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of shortness of breath | 3 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of decreased appetite | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Pain interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of memory problems | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of sadness or unhappiness | 2 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT-12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of bloating | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of shortness of breath | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Pain interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of sadness or unhappiness | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of bloating | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Dizziness interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of depression | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hiccups | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of insomnia | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of nausea | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of pain | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of dizziness | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of vomiting | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of hoarse voice | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Insomnia interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Memory problem interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Numbness or tingling in hands or feet interference | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of memory problems | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of hiccups | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of vomiting | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of fatigue | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of numbness/tingling in hands or feet | 3 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Depression interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of wheezing | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of nausea | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of decreased appetite | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Fatigue interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of heartburn | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Concentration problems interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of depression | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Sadness or happiness interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of bloating | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of anxiety | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of heartburn | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Shortness of breath interference | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of concentration problems | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Decreased appetite interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Anxiety interference | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of anxiety | 2 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Severity of sadness or unhappiness | 1 score on a scale |
| SBRT - 12 Months | Patient Reported Toxicity as Measured by PRO-CTCAE Assessment (Thoracic Cancer Sites) | Frequency of pain | 2 score on a scale |